WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, today announced that its financial results for the second
quarter of fiscal year 2013 will be released after the market close on
Wednesday, February 6, 2013, followed the same day by a conference call
and live webcast scheduled for 4:30 p.m. ET.
The conference call may be accessed by dialing (877) 303-9236 from the
U.S. and Canada, or (760) 666-3569 from international locations. A live
webcast will be available on the Investor Relations section of the
corporate website at http://www.psivida.com.
A replay of the call will be available beginning February 6, 2013 at
approximately 7:30 p.m. ET and ending on February 13, 2012. The replay
may be accessed by dialing (855) 859-2056 within the U.S. and Canada or
(404) 537-3406 from international locations, Conference ID Number:
95328173. A replay of the webcast will also be available on the
corporate website during that time.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a
controlled and steady rate for months or years. pSivida is currently
focused on treatment of chronic diseases of the back of the eye
utilizing its core technology systems, Durasert™ and BioSilicon™. The
injectable, sustained release micro-insert ILUVIEN® for the treatment of
chronic Diabetic Macular Edema (DME), licensed to Alimera Sciences,
Inc., has received marketing authorization in Austria, France, Germany,
Portugal, the U.K. and Spain, and is awaiting authorization in Italy.
The United States Food and Drug Administration (FDA) has cleared
pSivida's Investigational New Drug application (IND) to treat posterior
uveitis with the same micro-insert. An investigator-sponsored clinical
trial is ongoing for an injectable, bioerodible insert to treat glaucoma
and ocular hypertension. pSivida's two FDA-approved products, Retisert®
and Vitrasert®, are implants that provide long-term, sustained drug
delivery to treat two other chronic diseases of the retina.
For more information on pSivida, visit www.psivida.com.
In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak
President
Tel:
+1 (312) 943 1123
bjedynak@janispr.com
or
In
Australia:
pSivida Corp.
Brian Leedman
Vice President,
Investor Relations
+61 (0) 41 228 1780
brianl@psivida.com
Source: pSivida Corp.
News Provided by Acquire Media
